AVIR Q3 2023 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$18M

Operating Income

-$41M

Net Income

-$33M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$608M

Total Liabilities

$26M

Stockholders' Equity

$582M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$18M	$0	—
Operating Income	-$41M	-$16M	-150.5%
Net Income	-$33M	-$8M	-310.9%